|
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Clinical research trials and Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer. Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer clinical trial. Human subjects often get the best healthcare available for their Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer  Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
For Condition: Cancer
Status: No longer recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.
Details: OBJECTIVES: - Determine the maximum tolerated dose of suberoylanilide hydroxamic acid in patients with advanced solid tumors or hematologic malignancies. - Evaluate the pharmacokinetic profile of this drug in these patients. - Determine the effects of this drug on absorption in the fasting and non-fasting states in these patients. - Determine any anti-tumor effects of this drug in these patients. - Correlate clinical outcomes with histone acetylation in circulating mononuclear cells and tumor biopsy samples in patients treated with this drug. OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (solid tumor vs multiple myeloma or lymphoma vs leukemia or myelodysplastic syndromes). The initial 15-20 patients (in the solid tumor or multiple myeloma or lymphoma stratum) receive suberoylanilide hydroxamic acid (SAHA) IV over 2 hours on day 1 of week 0 and then orally once or twice daily beginning on day 1 of week 1. All remaining patients receive oral SAHA once or twice daily beginning on day 1 of week 1. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. In each stratum, cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed monthly for resolution of adverse events. PROJECTED ACCRUAL: A maximum of 114 patients (42 with solid tumors, 36 with lymphoma or multiple myeloma, and 36 with leukemia or myelodysplastic syndromes) will be accrued for this study within 1 year.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - One of the following diagnoses: - Histologically confirmed advanced primary or metastatic solid tumor, including, but not limited to, the following: - Androgen-independent prostate cancer - Breast cancer - Ovarian cancer - Head and neck cancer - Non-small cell lung cancer - Bladder cancer - Kidney cancer - Diagnosis of lymphoma, multiple myeloma, leukemia, or myelodysplastic syndromes (MDS), including, but not limited to, the following: - Intermediate-grade or follicular non-Hodgkin's lymphoma - Hodgkin's lymphoma - Patients with lymphoma or multiple myeloma must be ineligible for peripheral blood stem cell transplantation - For patients with solid tumors (except prostate cancer): - Disease progression based on development of new lesions or an increase in pre-existing lesions - Biochemical marker increase must not be sole criterion for disease progression - For prostate cancer patients only: - Disease progression based on rising prostate-specific antigen (PSA) values, transaxial imaging, or radionuclide scans - Increase in disease-related symptoms must not be sole manifestation of progression - Patients receiving an antiandrogen as part of first-line hormonal therapy must show disease progression off of the antiandrogen prior to study - Biochemical progression (at least 25% increase over range of values) defined as 1 of the following: - Rising PSA documented by at least 3 consecutive measurements obtained at least 1 week apart - Rising PSA documented by at least 2 consecutive measurements obtained more than 1 month apart - PSA at least 4 ng/mL - Testosterone no greater than 50 ng/mL - If no prior orchiectomy, must maintain castrate levels of testosterone - Disease must be refractory to standard therapy or for which no curative therapy exists - No active CNS or epidural tumors - Hormone receptor status: - Not specified NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age - 18 and over Sex - Male or female Menopausal status - Not specified Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - WBC at least 3,500/mm^3 - Platelet count at least 100,000/mm^3 (patients with solid tumors) - Platelet count greater than 25,000/mm^3 (patients with hematologic malignancy) - Absolute neutrophil count at least 500/mm^3 (patients with hematologic malignancy) Hepatic - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST and ALT no greater than 3 times ULN - PT no greater than 15 seconds Renal - Creatinine no greater than 2.0 mg/dL Cardiovascular - No New York Heart Association class III or IV heart disease Pulmonary - No severe debilitating pulmonary disease Other - No infection requiring IV antibiotics - No other severe medical problems that would preclude study participation - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics Chemotherapy - At least 4 weeks since prior chemotherapy Endocrine therapy - See Disease Characteristics - At least 4 weeks since prior ketoconazole - At least 2 weeks since prior steroids for patients with lymphoma - Concurrent gonadotropin-releasing hormone analogs or diethylstilbestrol to maintain castrate levels of testosterone allowed for prostate cancer patients - No concurrent ketoconazole Radiotherapy - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy to sole measurable lesion Surgery - See Disease Characteristics - No concurrent surgery Other - Recovered from all prior therapy - At least 4 weeks since prior palliative therapy for solid tumor patients with progressive metastatic disease (if present) - At least 4 weeks since prior investigational anticancer therapeutic drugs - At least 2 weeks since prior conventional cytotoxic therapy for patients with leukemia or MDS - At least 4 weeks since prior investigational therapy for patients with leukemia or MDS - No other concurrent investigational drugs - No other concurrent anticancer agents
Total Enrollment:
Location and Contact Information:
Overall Study Official:
WilliamKelly, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000256306; MSKCC-01021,NCI-G02-2099,ATON-0101
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045006
Other Cancer Studies:
1. 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
2. Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
3. A Phase I Study of Infusional Paclitaxel with the P-Glycoprotein Antagonist PSC 833
4. A Phase I Study of ARQ 501 in Subjects with Cancer
5. Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Related Studies:
Other Cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
|
|
|
|
|
|
|
|
